SciClone Pharmaceuticals to Report First Quarter 2009 Results on May 11

* Reuters is not responsible for the content in this press release.

Wed Apr 29, 2009 5:30pm EDT 

  FOSTER CITY, CA, Apr 29 (MARKET WIRE) -- 
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report first quarter 2009 results on Monday, May 11, 2009.
SciClone will host a conference call to give a business and product
update at 4:30 pm ET that day. The call will be hosted by Friedhelm
Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice President
and CFO.


LIVE CALL:      877-627-6544 (U.S./Canada)
                719-325-4858 (International)
REPLAY:         888-203-1112 (U.S./Canada)
                719-457-0820 (International)
                Passcode:  7704836
                (Replay available from Monday, May 11, 2009 at 8:00 p.m.
                ET until 11:59 p.m. ET on Monday, June 8, 2009)

    
The conference call will contain forward-looking statements.
Interested parties who wish to listen to the webcast should visit the
Investor Relations section of SciClone's website at www.sciclone.com. The
information provided on the teleconference is only accurate at the time of
the conference call, and SciClone will take no responsibility for
providing updated information except as required by law.

    About SciClone

    SciClone Pharmaceuticals (NASDAQ: SCLN) is a for-profit, global
biopharmaceutical company with a substantial international business and a
product portfolio of novel therapies for cancer and infectious diseases.
SciClone is focused on achieving international sales growth, a
cost-containing clinical development strategy and focused expense
management. ZADAXIN is sold in over 30 countries for the treatment of
hepatitis B and hepatitis C, certain cancers and as a vaccine adjuvant.
SciClone's pipeline of phase 2 and 3 drug candidates includes thymalfasin
for stage IV melanoma, for which SciClone has reached agreement with the
FDA on the design of a phase 3 trial; RP101 in phase 2 in a phase 2 trial
for the treatment of pancreatic cancer; SCV-07 in a phase 2 trials for the
delay of onset of severe oral mucositis in patients receiving
chemoradiation therapy for the treatment of cancers of the head and neck;
and, awaiting approval in China, DC Bead(TM) for the treatment of liver
cancer. For additional information, please visit www.sciclone.com.

    

Corporate Contact:
Ana Kapor
SciClone Pharmaceuticals, Inc.
650.358.3437
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.